Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another shot ...

Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...

Novo Nordisk NOVO.B3.59%increase; green up pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Shares of Novo Nordisk jumped nearly 7% on Wednesday after ... Sales of the company's popular Wegovy obesity drug rose 83% annually at constant exchange rates to 17.36 billion Danish kroner ...

Novo Nordisk on Wednesday reported a better-than ... Sales of the company's popular Wegovy obesity drug hit 17.36 billion Danish kroner over the period, slightly below the 18.51 billion Danish ...

Hims & Hers stock surges after Novo Nordisk announces Wegovy will be offered through telehealth platforms as shortages ease ...

The US Food and Drug Administration seized fake Ozempic injections. This happened on April 9, 2025. Novo Nordisk warned about ...

Curiously, this is both good news and bad news for Novo Nordisk stock. On the good news front, it stands to reason that if Ozempic is already a popular product ... it's to make the most of it.